Seven Bridges Stock
Biomedical Data Science Company
Sign up today and learn more about Seven Bridges Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Seven Bridges Stock
Seven Bridges is the industry-leading infrastructure and data analytics company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, services, and support expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaborations with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale. Named one of the world's smartest companies by MIT Technology Review, and a three-time Bio-IT World Best of Show winner, Seven Bridges has offices in Belgrade, Boston, Istanbul, and San Francisco.
Investors
Kryssen Capital
First Star Ventures
Funding History
| September 2014 | $3.0M |
|---|---|
| February 2016 | $45.0M |
| April 2018 | $50.0M |
| April 2021 | $15.0M |
Management
Chief Executive Officer
William Moss
Chief Financial Officer
Robert Shay
Chief Technology Officer
David Ramos
Press
businesswire - Nov, 2 2023
Velsera Makes NVIDIA Parabricks Tools Available for Global Researchers on the Seven Bridges Platformbusinesswire - Oct, 4 2023
Velsera to Showcase Seven Bridges Bioinformatics Platform at BioTechX Europebusinesswire - Jan, 24 2023
New Company, Velsera, Represents Summa Equity's Vision to Improve Global Health Outcomesgenomeweb - Jan, 14 2023
Pierian, Seven Bridges, UgenTec Acquired, Merged to Become Velseragenomeweb - Apr, 20 2022
Seven Bridges, Google Cloud Partner on Brazilian Reference Genome ProjectEquityZen Recognized As:
